Integragen (France) Today
| ALINT Stock | EUR 0.44 0.01 2.22% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Integragen is selling at 0.44 as of the 24th of November 2024; that is 2.22% down since the beginning of the trading day. The stock's last reported lowest price was 0.44. Integragen has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Integragen are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of November 2023 and ending today, the 24th of November 2024. Click here to learn more.
IntegraGen SA provides human genome analysis services for academic and private laboratories in France and the United States. IntegraGen SA was founded in 2000 and is headquartered in vry, France. INTEGRAGEN operates under Biotechnology classification in France and is traded on Paris Stock Exchange. The company has 6.6 M outstanding shares. More on Integragen
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Integragen Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Integragen's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Integragen or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Larry Yost |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Integragen (ALINT) is traded on Euronext Paris in France and employs 52 people. The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Integragen's market, we take the total number of its shares issued and multiply it by Integragen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Integragen operates under Biotechnology sector and is part of Health Care industry. The entity has 6.6 M outstanding shares.
Integragen has accumulated about 1.84 M in cash with (2.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Integragen Probability Of Bankruptcy
Ownership AllocationIntegragen retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.9 (percent) of Integragen outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event.
Check Integragen Ownership Details
Integragen Risk Profiles
Although Integragen's alpha and beta are two of the key measurements used to evaluate Integragen's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.41 | |||
| Standard Deviation | 5.08 | |||
| Variance | 25.85 | |||
| Risk Adjusted Performance | (0.05) |
Integragen Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Integragen without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
| All Next | Launch Module |
Integragen Corporate Directors
| Emmanuel Martin | Director Sales & Marketing for the Services Business Unit | Profile | |
| Gerald Wagner | Director | Profile | |
| Laurence Lamotte | Director of Administration and Finance | Profile | |
| Benoit Adelus | Director | Profile |
Additional Tools for Integragen Stock Analysis
When running Integragen's price analysis, check to measure Integragen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integragen is operating at the current time. Most of Integragen's value examination focuses on studying past and present price action to predict the probability of Integragen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integragen's price. Additionally, you may evaluate how the addition of Integragen to your portfolios can decrease your overall portfolio volatility.